HER2-positive tumors have traditionally been considered “cold” tumors due to their low mutational burden [9], which partially explains why immunotherapies have not been studied as extensively in these tumors as in “hot” tumors (e.g., melanoma). Here, ERBB2 is linked to melanoma.